Search Results
Your search for ,USE matches 11056 pages
Showing 11051 - 11056Bevacizumab Approved as Combination Therapy for Metastatic Colorectal Cancer after Progression on First-line Bevacizumab Therapy
On January 23, 2013, the FDA approved bevacizumab (Avastin) for use in combination with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy for the treatment of patients with metastatic colorectal cancer whose disease has progressed on a first-line bevacizumab-containing...
Genetic Basis of High-risk Childhood Cancer Points to Possible New Drug Treatment Strategy
Research led by St. Jude Children’s Research Hospital scientists has identified a possible lead in treatment of two childhood leukemia subtypes known for their dramatic loss of chromosomes and poor treatment outcomes. The findings also provide the first evidence of the genetic basis for ...
New Model May Help Predict Response to Chemotherapy for Colorectal Cancer
Scientists may be able to better predict which patients with colorectal cancer will respond to chemotherapy using a new mathematical model that measures the amount of stress required for a cancer cell to die without harming healthy tissue. The results of this study are published in Cancer Research, ...
Patients with NSCLC Have Improved Survival If They Use Beta-blockers While Receiving Radiotherapy
Patients with non–small cell lung cancer (NSCLC) have improved survival outcomes if they are taking beta-blockers while receiving radiotherapy, according to a study of 722 patients recently published in Annals of Oncology. Researchers at the University of Texas MD Anderson Cancer Center in...
Report to the Nation Shows U.S. Cancer Death Rates Continue to Drop
The Annual Report to the Nation on the Status of Cancer, 1975–2009, shows that overall cancer death rates continued to decline in the United States among both men and women, among all major racial and ethnic groups, and for all of the most common cancer sites, including lung, colon and...
Improving Outcomes for Patients With Non–Small Cell Lung Cancer
For over a decade, the treatment landscape of non–small cell lung cancer (NSCLC) has been rapidly evolving. It now includes testing for genetic alterations and the use of targeted therapies and immunotherapies, with new targets and treatments still being discovered and approved. In this six-part...
